S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00066794|
Recruitment Status : Completed
First Posted : August 7, 2003
Last Update Posted : March 6, 2015
RATIONALE: Drugs used in chemotherapy, such as cyclosporine, daunorubicin, and cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving cyclosporine together with daunorubicin and cytarabine works in treating older patients with untreated acute myeloid leukemia.
|Condition or disease||Intervention/treatment||Phase|
|Leukemia||Biological: filgrastim Biological: sargramostim Drug: cyclosporine Drug: cytarabine Drug: daunorubicin hydrochloride||Phase 2|
- Determine the safety and efficacy of cyclosporine, daunorubicin, and cytarabine in older patients with previously untreated acute myeloid leukemia.
- Determine the frequency and severity of toxic effects of this regimen in these patients.
- Determine, preliminarily, the frequency and prognostic significance of functional and phenotypic P-glycoprotein expression and cytogenetics in patients treated with this regimen.
- Determine, preliminarily, the pharmacokinetic characteristics of this regimen in these patients.
OUTLINE: This is a multicenter study.
- Induction therapy: Patients receive cyclosporine IV and daunorubicin IV continuously on days 1-3 and cytarabine IV continuously on days 1-7. Patients who achieve complete response (CR) after chemotherapy receive filgrastim (G-CSF) or sargramostim (GM-CSF) IV or subcutaneously beginning on day 15 or 20 and continuing until blood counts recover. Patients who maintain CR after 2 courses of induction therapy proceed to consolidation therapy.
- Consolidation therapy: Patients receive treatment as in induction therapy with cyclosporine and daunorubicin on days 1-2 and cytarabine on days 1-5. Patients achieving CR receive an additional course of chemotherapy beginning at least 14 days after completion of the first course of cytarabine.
Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually for 3 years.
PROJECTED ACCRUAL: A total of 25-64 patients will be accrued for this study within 13 months.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||69 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Study Of Induction With Daunorubicin, Cytarabine, And Cyclosporine All By Continuous IV Infusion For Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) In Patients Of Age 56 Or Older|
|Study Start Date :||July 2004|
|Actual Primary Completion Date :||February 2007|
|Actual Study Completion Date :||January 2010|
- Biological: filgrastim
5 mcg/kg/d IV or SC starting apx day 15
- Biological: sargramostim
250 mcg/kg/d IV or SC starting apx day 15
- Drug: cyclosporine
ind: 6 mg/kg load IV over 2 hrs days 0-2 followed by 16 mg/dg/d continuous IV days 2-74 consol: 6 mg/kg load IV over 2 hrs days 0-2 followed by 16 mg/dg/d continuous IV days 2-50
- Drug: cytarabine
ind: 200 mg/m2/d cont IV days 2-74
- Drug: daunorubicin hydrochloride
ind: 45 mg/m2/d cont IV days 2-74
- Complete remission (CR) [ Time Frame: After induction therapy is completed ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00066794
|Principal Investigator:||Thomas R. Chauncey, MD, PhD||VA Puget Sound Health Care System|
|Principal Investigator:||Cheryl L. Willman, MD||University of New Mexico Cancer Center|
|Principal Investigator:||Marilyn L. Slovak, PhD||City of Hope Comprehensive Cancer Center|